Shanghai Pharmaceuticals Holding Co., Ltd (SHA:601607)
18.81
-0.09 (-0.48%)
Aug 15, 2025, 3:00 PM CST
SHA:601607 Revenue
Shanghai Pharmaceuticals Holding had revenue of 70.76B CNY in the quarter ending March 31, 2025, with 0.87% growth. This brings the company's revenue in the last twelve months to 275.86B, up 4.41% year-over-year. In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B with 5.75% growth.
Revenue (ttm)
275.86B
Revenue Growth
+4.41%
P/S Ratio
0.23
Revenue / Employee
5.58M
Employees
49,402
Market Cap
63.20B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 275.25B | 14.96B | 5.75% |
Dec 31, 2023 | 260.30B | 28.31B | 12.21% |
Dec 31, 2022 | 231.98B | 16.16B | 7.49% |
Dec 31, 2021 | 215.82B | 23.92B | 12.46% |
Dec 31, 2020 | 191.91B | 5.34B | 2.86% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 29.19B |
WuXi AppTec | 41.48B |
Shenzhen Mindray Bio-Medical Electronics | 35.59B |
Sichuan Biokin Pharmaceutical | 5.82B |
Aier Eye Hospital Group | 21.81B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
Shanghai United Imaging Healthcare | 10.43B |
Yunnan Baiyao Group Co.,Ltd | 40.10B |
Shanghai Pharmaceuticals Holding News
- 8 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 8 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha